These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28937536)

  • 1. Enoxaparin Population Pharmacokinetics in the First Year of Life.
    Moffett BS; Galati M; Mahoney D; Lee-Kim Y; Teruya J; Shah MD; Yee DL
    Ther Drug Monit; 2017 Dec; 39(6):632-639. PubMed ID: 28937536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
    Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
    Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
    Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR
    Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review.
    Yost RJ; Haan BJ; Mangan KC
    Pharmacotherapy; 2018 Nov; 38(11):e82-e86. PubMed ID: 30129107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment.
    Hulot JS; Vantelon C; Urien S; Bouzamondo A; Mahé I; Ankri A; Montalescot G; Lechat P
    Ther Drug Monit; 2004 Jun; 26(3):305-10. PubMed ID: 15167633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
    Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
    J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.
    Green B; Greenwood M; Saltissi D; Westhuyzen J; Kluver L; Rowell J; Atherton J
    Br J Clin Pharmacol; 2005 Mar; 59(3):281-90. PubMed ID: 15752373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
    Ramos-Esquivel A; Salazar-Sánchez L
    Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK; Shelton CM; Sahni JK; Christensen ML
    Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Enoxaparin After Renal Transplantation in Pediatric Patients.
    Damamme A; Urien S; Borgel D; Lasne D; Krug P; Krid S; Charbit M; Salomon R; Treluyer JM; Boyer O
    J Clin Pharmacol; 2018 Dec; 58(12):1597-1603. PubMed ID: 30256422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot Study.
    Dekker KR; Myers BL; Barras MA
    Ther Drug Monit; 2016 Feb; 38(1):59-63. PubMed ID: 26766749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.
    Berges A; Laporte S; Epinat M; Zufferey P; Alamartine E; Tranchand B; Decousus H; Mismetti P;
    Br J Clin Pharmacol; 2007 Oct; 64(4):428-38. PubMed ID: 17509040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.
    Malinoski D; Jafari F; Ewing T; Ardary C; Conniff H; Baje M; Kong A; Lekawa ME; Dolich MO; Cinat ME; Barrios C; Hoyt DB
    J Trauma; 2010 Apr; 68(4):874-80. PubMed ID: 20386282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
    Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin and antifactor Xa levels in pediatric acute burn patients.
    Brown A; Faraklas I; Ghanem M; Cochran A
    J Burn Care Res; 2013; 34(6):628-32. PubMed ID: 24043233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin and antifactor Xa levels in acute burn patients.
    Lin H; Faraklas I; Cochran A; Saffle J
    J Burn Care Res; 2011; 32(1):1-5. PubMed ID: 21124231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.
    Brophy DF; Wazny LD; Gehr TW; Comstock TJ; Venitz J
    Pharmacotherapy; 2001 Feb; 21(2):169-74. PubMed ID: 11213853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A; Held K; Oschman A
    Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.